Infliximab therapy in Crohn's disease: safety issues
Infliximab has become a valuable addition to the therapeutic arsenal for Crohn's disease. Although the rate of adverse events was relatively low in the premarketing trials, several investigators have recently reported experience in large groups of patients. This has shed more light on safety as...
Gespeichert in:
| Veröffentlicht in: | Netherlands journal of medicine 2003-04, Vol.61 (4), p.100-104 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 104 |
|---|---|
| container_issue | 4 |
| container_start_page | 100 |
| container_title | Netherlands journal of medicine |
| container_volume | 61 |
| creator | HOMMES, D. W VAN DEVENTER, S. J. H |
| description | Infliximab has become a valuable addition to the therapeutic arsenal for Crohn's disease. Although the rate of adverse events was relatively low in the premarketing trials, several investigators have recently reported experience in large groups of patients. This has shed more light on safety aspects of infliximab therapy, which should change the approach towards patients prior to infliximab infusion. This review discusses some immunological aspects that are relevant for infliximab therapy and provides guidelines for daily practice. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_12852717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>12852717</sourcerecordid><originalsourceid>FETCH-LOGICAL-g262t-381198b0e1f56217461d43ace221eda308d5004046e07bf28064bdb0ffd242843</originalsourceid><addsrcrecordid>eNpFjsFKxDAURYMoTh39BelGXBXee0mT1J0UHQcG3Oh6SJrEqXRq6euA8_cWHHF1F_dwOGciQ2uoqEDjuchAAhRUGbMQV8yfAKBNVV6KBZItyaDJhFr3qWu_273z-bSLoxuOedvn9fi16-85Dy1Hx_EhZ5fiNF_Mh8jX4iK5juPNaZfi_fnprX4pNq-rdf24KT5I01RIi1hZDxFTqQmN0hiUdE0kwhicBBtKAAVKRzA-kQWtfPCQUiBFVsmluP31Dge_j2E7jHPneNz-5c_A3Qlw3Lguja5vWv7nlDYWrZQ_Cq9NNw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Infliximab therapy in Crohn's disease: safety issues</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>HOMMES, D. W ; VAN DEVENTER, S. J. H</creator><creatorcontrib>HOMMES, D. W ; VAN DEVENTER, S. J. H</creatorcontrib><description>Infliximab has become a valuable addition to the therapeutic arsenal for Crohn's disease. Although the rate of adverse events was relatively low in the premarketing trials, several investigators have recently reported experience in large groups of patients. This has shed more light on safety aspects of infliximab therapy, which should change the approach towards patients prior to infliximab infusion. This review discusses some immunological aspects that are relevant for infliximab therapy and provides guidelines for daily practice.</description><identifier>ISSN: 0300-2977</identifier><identifier>EISSN: 1872-9061</identifier><identifier>PMID: 12852717</identifier><language>eng</language><publisher>Alphen aan den Rijn: Van zuiden</publisher><subject>Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Crohn Disease - therapy ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Hypersensitivity, Delayed - etiology ; Immunopathology ; Immunotherapy (general aspects) ; Infliximab ; Infusions, Intravenous - adverse effects ; Medical sciences ; Other diseases. Semiology ; Safety ; Serum Sickness - etiology ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tuberculosis - etiology ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Netherlands journal of medicine, 2003-04, Vol.61 (4), p.100-104</ispartof><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14678183$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12852717$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOMMES, D. W</creatorcontrib><creatorcontrib>VAN DEVENTER, S. J. H</creatorcontrib><title>Infliximab therapy in Crohn's disease: safety issues</title><title>Netherlands journal of medicine</title><addtitle>Neth J Med</addtitle><description>Infliximab has become a valuable addition to the therapeutic arsenal for Crohn's disease. Although the rate of adverse events was relatively low in the premarketing trials, several investigators have recently reported experience in large groups of patients. This has shed more light on safety aspects of infliximab therapy, which should change the approach towards patients prior to infliximab infusion. This review discusses some immunological aspects that are relevant for infliximab therapy and provides guidelines for daily practice.</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Crohn Disease - therapy</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Hypersensitivity, Delayed - etiology</subject><subject>Immunopathology</subject><subject>Immunotherapy (general aspects)</subject><subject>Infliximab</subject><subject>Infusions, Intravenous - adverse effects</subject><subject>Medical sciences</subject><subject>Other diseases. Semiology</subject><subject>Safety</subject><subject>Serum Sickness - etiology</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tuberculosis - etiology</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0300-2977</issn><issn>1872-9061</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFjsFKxDAURYMoTh39BelGXBXee0mT1J0UHQcG3Oh6SJrEqXRq6euA8_cWHHF1F_dwOGciQ2uoqEDjuchAAhRUGbMQV8yfAKBNVV6KBZItyaDJhFr3qWu_273z-bSLoxuOedvn9fi16-85Dy1Hx_EhZ5fiNF_Mh8jX4iK5juPNaZfi_fnprX4pNq-rdf24KT5I01RIi1hZDxFTqQmN0hiUdE0kwhicBBtKAAVKRzA-kQWtfPCQUiBFVsmluP31Dge_j2E7jHPneNz-5c_A3Qlw3Lguja5vWv7nlDYWrZQ_Cq9NNw</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>HOMMES, D. W</creator><creator>VAN DEVENTER, S. J. H</creator><general>Van zuiden</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20030401</creationdate><title>Infliximab therapy in Crohn's disease: safety issues</title><author>HOMMES, D. W ; VAN DEVENTER, S. J. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g262t-381198b0e1f56217461d43ace221eda308d5004046e07bf28064bdb0ffd242843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Crohn Disease - therapy</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Hypersensitivity, Delayed - etiology</topic><topic>Immunopathology</topic><topic>Immunotherapy (general aspects)</topic><topic>Infliximab</topic><topic>Infusions, Intravenous - adverse effects</topic><topic>Medical sciences</topic><topic>Other diseases. Semiology</topic><topic>Safety</topic><topic>Serum Sickness - etiology</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tuberculosis - etiology</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOMMES, D. W</creatorcontrib><creatorcontrib>VAN DEVENTER, S. J. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Netherlands journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOMMES, D. W</au><au>VAN DEVENTER, S. J. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Infliximab therapy in Crohn's disease: safety issues</atitle><jtitle>Netherlands journal of medicine</jtitle><addtitle>Neth J Med</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>61</volume><issue>4</issue><spage>100</spage><epage>104</epage><pages>100-104</pages><issn>0300-2977</issn><eissn>1872-9061</eissn><abstract>Infliximab has become a valuable addition to the therapeutic arsenal for Crohn's disease. Although the rate of adverse events was relatively low in the premarketing trials, several investigators have recently reported experience in large groups of patients. This has shed more light on safety aspects of infliximab therapy, which should change the approach towards patients prior to infliximab infusion. This review discusses some immunological aspects that are relevant for infliximab therapy and provides guidelines for daily practice.</abstract><cop>Alphen aan den Rijn</cop><pub>Van zuiden</pub><pmid>12852717</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-2977 |
| ispartof | Netherlands journal of medicine, 2003-04, Vol.61 (4), p.100-104 |
| issn | 0300-2977 1872-9061 |
| language | eng |
| recordid | cdi_pubmed_primary_12852717 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Biological and medical sciences Crohn Disease - therapy Gastroenterology. Liver. Pancreas. Abdomen Humans Hypersensitivity, Delayed - etiology Immunopathology Immunotherapy (general aspects) Infliximab Infusions, Intravenous - adverse effects Medical sciences Other diseases. Semiology Safety Serum Sickness - etiology Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tuberculosis - etiology Tumor Necrosis Factor-alpha - immunology |
| title | Infliximab therapy in Crohn's disease: safety issues |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Infliximab%20therapy%20in%20Crohn's%20disease:%20safety%20issues&rft.jtitle=Netherlands%20journal%20of%20medicine&rft.au=HOMMES,%20D.%20W&rft.date=2003-04-01&rft.volume=61&rft.issue=4&rft.spage=100&rft.epage=104&rft.pages=100-104&rft.issn=0300-2977&rft.eissn=1872-9061&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E12852717%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12852717&rfr_iscdi=true |